Clinical stage biotechnology company TORL BioTherapeutics LLC announced on Tuesday the appointment of Howard A. 'Skip' Burris III, MD, FACP, FASCO as a new board member.
Dr Burris is president and chief medical officer for the Sarah Cannon Research Institute (SCRI). He served as the elected president of the American Society of Clinical Oncology (ASCO), holding leadership positions both before and after his ASCO president role, and is an active member of the ASCO community. Dr Burris is also the chair of the board for the ASCO Conquer Cancer Foundation. He was director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center and was an associate professor at The University of Texas Health Science Center. He also served in the US Army and attained the rank of lieutenant colonel.
Mark J Alles, chairman and CEO at TORL BioTherapeutics, said: "We are thrilled to have Skip join TORL's board. He is a renowned medical oncologist with decades of success developing first-in-human cancer therapies, many now FDA approved and that have become global standards of care."
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Oxford BioDynamics reports high accuracy for blood-based colorectal cancer test
Valneva secures UK approval for world's first chikungunya vaccine
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
BrainCool secures market approval for BrainCool System in Malaysia
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
Polarean Imaging expands reach with Taiwanese distribution deal
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer